Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cause-specific mortality in patients with psoriasis and psoriatic arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose metabolism in patients with psoriasis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cohort profile: the clinical 'Psoriasis in Adolescents' (PIA) cohort in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA).

OBJECTIVES: This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA.

METHODS: Individuals with a hospital-based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause-specific mortality in patients with psoriasis or PsA.

RESULTS: Death rates per 1000 patient-years (with 95% confidence intervals) vs. controls were 22·3 (19·7-24·9) vs. 13·9 (11·8-16·0) for patients with psoriasis and 10·8 (8·9-12·8) vs. 11·6 (9·6-13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001).

CONCLUSIONS: Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.

Original languageEnglish
JournalBritish Journal of Dermatology
Volume180
Issue number1
Pages (from-to)100-107
Number of pages8
ISSN0007-0963
DOIs
Publication statusPublished - Jan 2019

ID: 58099364